azomycin has been researched along with pr-104 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennewith, KL; Cairns, RA; Chang, DT; Denko, NC; Giaccia, AJ; Graves, EE | 1 |
| Cecic, IK; Erler, JT; Felsher, D; Giaccia, AJ; Graves, EE; Le, QT; Sayles, L; Sweet-Cordero, A; Tran, PT; Vilalta, M | 1 |
| Ashoorzadeh, A; Ding, K; Guise, CP; Lin, WH; Mowday, AM; Patterson, AV; Smaill, JB; Wu, DH; Yuan, R | 1 |
| Andreeff, M; Benito, J; Borthakur, G; Bueso-Ramos, C; Cortes, J; Coveler, A; Daver, N; Estey, EH; Faderl, S; Feliu, J; Gu, Y; Gutheil, JC; Jabbour, E; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Kornblau, S; Lu, H; Melink, TJ; Nguyen, HQ; Pemmaraju, N; Ravandi, F; Thall, PF; Thomas, D; Wei, C; Wilson, WR; Yi, CA | 1 |
1 review(s) available for azomycin and pr-104
| Article | Year |
|---|---|
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Topics: Anthraquinones; Antineoplastic Agents; Aziridines; Cell Hypoxia; Humans; Indolequinones; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Nitrogen Mustard Compounds; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Tirapazamine; Triazines | 2014 |
1 trial(s) available for azomycin and pr-104
| Article | Year |
|---|---|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Biomarkers; Bone Marrow; Carbonic Anhydrase IX; Carbonic Anhydrases; Enterocolitis; Female; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Nitroimidazoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Recurrence; Remission Induction; Thrombocytopenia | 2015 |
2 other study(ies) available for azomycin and pr-104
| Article | Year |
|---|---|
Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Humans; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Neoplasms; Nitrogen Mustard Compounds; Nitroimidazoles; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Hypoxia in models of lung cancer: implications for targeted therapeutics.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Electrodes; Histones; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitrogen Mustard Compounds; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Proto-Oncogene Proteins c-myc; ras Proteins | 2010 |